Please login to the form below

Addressing Climate Impact: The Healthcare Paradox

For the healthcare and pharmaceutical industry, the impact of climate change is twofold – responding to the increased risk of certain diseases and conditions and decarbonising their own processes and products to prevent worsening impact.

Andrew Harrison
Managing Director, Hanover Health

For the healthcare and pharmaceutical industry, the impact of climate change is twofold – responding to the increased risk of certain diseases and conditions and decarbonising their own processes and products to prevent worsening impact.

Observable effects of climate change are already being felt – for example, the Lancet’s 2019 report on the infection rates of dengue fever (expressed as vectorial capacity for transmissions) showed that nine of the ten most suitable years for transmission on record since 1950 have occurred since 2000. In 2018 there were 220 million more heatwave exposures affecting older populations increasing risks of heart and kidney stress and disease and stroke.

Yet, paradoxically, developing and delivering solutions to these challenges has a climate cost. Analysis has suggested that combined CO2 emissions from hospitals, health services and medical supply chains across the OECD group of market economies plus China and India comprise 4% of total global emissions footprint – greater than either aviation or shipping.

The NHS has been found to produce 5.4% of England’s total carbon emissions. For healthcare providers, challenges lie in areas such as transport, building efficiency and waste reduction – where high-quality waste products in operating theatres that could be recycled largely end up being labelled as infectious clinical waste and are incinerated at a high financial and environmental cost. Similarly, some procedures are particularly carbon intensive. Hospitals have been exploring solutions ranging from retrofitting heat recovery technology to dialysis machines, to switching operating room anaesthetics, which account for almost a third of the UK’s health and social care sector emissions, to less-polluting gas. Linked options include introducing technology to capture these gases and seeking alternative clinical techniques.

There is a clear role for industry to support healthcare providers through innovative product design. Boehringer Ingelheim recently introduced the first reusable, propellant-free inhaler for patients with asthma and COPD, supporting objectives of carbon and plastic waste reduction. An associated study suggested that the reusability of the inhaler reduces its carbon footprint by as much as 71% and should mean that over a million fewer inhalers are needed annually.

The challenge of producing sustainable medicines is also being explored by the Innovative Medicines Initiative. The scheme represents Europe’s largest public-private partnership in life sciences, between the European Commission and the European pharmaceutical industry. Its €26.m (£21.2m) CHEM21 project brings together six pharmaceutical companies, thirteen universities and four small and mid-sized enterprises from across Europe to develop sustainable biological and chemical alternatives to finite materials, such as precious metals, which are currently used as catalysts in the manufacture of medicines.
To minimise wider environmental impacts, efforts are being made to introduce biotechnology to the manufacturing processes for medicine production.

Nonetheless, it is critical that pharmaceutical companies retain a focus on driving decarbonisation and best practice sustainability in-house as well as in product design. In 2015 the global pharmaceutical industry produced 55% more CO2 than the automotive industry1. The NHS Sustainable Development Unit’s 2018 National Resources Footprint2 stated that pharmaceuticals are the second largest producer of both water footprint and carbon emissions (12.1%) relating to the healthcare service in England.

The shift to a far more rapid rate of decarbonisation across the pharmaceutical industry and the broader healthcare sector will require significant action. But trends have shown that focused efforts can deliver results on decarbonisation, and indeed can be delivered alongside economic growth and expansion of service. In the NHS emissions from health and social care have been cut by 18.5%3 since 2007, despite clinical activity rising by over a quarter over the same period.

Interestingly, the report on global pharmaceutical performance4 demonstrated that the companies leading on emissions (Amgen, Johnson & Johnson and Roche Holding) were also three of the most profitable in the sector. This is clear proof that there is economic opportunity in innovating for the future.

This article was originally published in 'Net Zero Unpacked: An Essential Guide for Business Strategy & Corporate Communications.

The report contains insights from leading companies both inside and outside of the healthcare industry including Novo Nordisk, Apple, Lucozade Ribena Suntory, Facebook, and Sky, on how businesses are acting to support Net Zero.

1 International comparison of health care carbon footprints: Peter-Paul Pichler, Ingram S Jaccard, Ulli Weisz and Helga Weisz,


3 Natural Resource Footprint 2018,

4 IDC FutureScape: Worldwide Datacenter 2019 Predictions,

26th February 2020



Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications